Seven biotech companies are working on clinical drug candidates to treat hepatitis B, a serious liver infection affecting 254 million people worldwide. Companies like Assembly Biosciences and Barinthus Biotherapeutics are using innovative technologies such as capsid assembly modulators and antigen-specific immunotherapy to develop new treatments. These breakthroughs offer hope for a cure and improved management of the disease.
Forecast for 6 months: Within the next six months, we can expect to see the results of Assembly Biosciences’ phase 1b study for ABI-4334, which could lead to a significant breakthrough in hepatitis B treatment.
Forecast for 1 year: By the end of the year, we may see the approval of a new hepatitis B treatment, potentially from Assembly Biosciences or Barinthus Biotherapeutics, which could revolutionize the way the disease is managed.
Forecast for 5 years: In the next five years, we can expect to see a significant reduction in hepatitis B-related deaths and liver transplants, thanks to the development of effective treatments and improved management strategies.
Forecast for 10 years: By 2034, hepatitis B may be considered a manageable disease, with effective treatments available and a significant reduction in the number of people living with the virus.
